Literature DB >> 9387804

Neuroleptic malignant syndrome in parkinsonian patients: risk factors.

S Kuno1, E Mizuta, S Yamasaki.   

Abstract

A syndrome resembling the neuroleptic malignant syndrome (NMS) is known to develop occasionally following interruption of dopaminergic medications in patients with Parkinson's disease. However, NMS can develop even without withdrawal of antiparkinsonian drugs. In parkinsonian patients who continually received dopaminergic medications, the development of NMS occurred exclusively in warm seasons, May to August. The development of NMS could occur at any season in association with the cessation of dopaminergic drugs. A female parkinsonian patient showed two episodes of NMS during the premenstrual period. It is suggested that hot weather or dehydration and aggravation of parkinsonism premenstrually constitute risk factors for the development of NMS, in addition to withdrawal of antiparkinsonian drugs.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9387804     DOI: 10.1159/000113484

Source DB:  PubMed          Journal:  Eur Neurol        ISSN: 0014-3022            Impact factor:   1.710


  6 in total

1.  Parkinsonism-hyperpyrexia syndrome not related to antiparkinsonian treatment withdrawal during the 2003 summer heat wave.

Authors:  C Gaig; M J Martí; E Tolosa; M J Gómez-Choco; S Amaro
Journal:  J Neurol       Date:  2005-03-21       Impact factor: 4.849

2.  Risperidone-induced neuroleptic malignant syndrome in neurodegenerative disease: a case report.

Authors:  Daniel Johnson; Aby Z Philip; Dennis J Joseph; Roy Varghese
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2007

Review 3.  Treatment of movement disorder emergencies.

Authors:  Steven J Frucht
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

Review 4.  Movement disorder emergencies.

Authors:  Steven J Frucht
Journal:  Curr Neurol Neurosci Rep       Date:  2005-07       Impact factor: 5.081

Review 5.  Movement disorder emergencies.

Authors:  Kathleen L Poston; Steven J Frucht
Journal:  J Neurol       Date:  2008-08       Impact factor: 4.849

6.  Neuroleptic malignant syndrome: a review for neurohospitalists.

Authors:  Brian D Berman
Journal:  Neurohospitalist       Date:  2011-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.